Skandinaviska Enskilda Banken (SEB)’s Vanda Pharmaceuticals VNDA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45,280	Closed	-$776K	–	1076
2021 Q3	$776K	Sell	45,280 -62,320	-58%	-$1.09M	﹤0.01%	824
2021 Q2	$2.31M	Hold	107,600	–	–	0.01%	626
2021 Q1	$1.62M	Hold	107,600	–	–	0.01%	720
2020 Q4	$1.41M	Sell	107,600 -20,900	-16%	-$252K	0.01%	745
2020 Q3	$1.24M	Sell	128,500 -29,100	-18%	-$311K	0.01%	686
2020 Q2	$1.8M	Buy	157,600 +8,200	+5%	+$92.8K	0.01%	591
2020 Q1	$1.55M	Buy	+149,400	New	+$1.85M	0.02%	539
2016 Q2	–	Sell	-120,600	Closed	-$1.01M	–	728
2016 Q1	$1.01M	Sell	120,600 -301,700	-71%	-$2.48M	0.01%	585
2015 Q4	$4.08M	Buy	+422,300	New	+$4.21M	0.05%	246

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s VNDA Position: Q4 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Vanda Pharmaceuticals (VNDA) in Q4 2021, closing a stake of 45,280 shares — an estimated $776K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in VNDA in Q4 2015 and held it in 9 quarters. The position peaked at $4.08M in Q4 2015. 198 funds tracked by Wall St. Rank hold VNDA as of Q4 2021.

Skandinaviska Enskilda Banken (SEB) reported no remaining Vanda Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 45,280 Vanda Pharmaceuticals shares in Q4 2021, an estimated $776K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 9 quarters.
Skandinaviska Enskilda Banken (SEB)'s Vanda Pharmaceuticals position peaked at $4.08M in Q4 2015.
198 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2021, filed 10 Feb 2022.